Blueberries improve biomarkers of cardiometabolic function in participants with metabolic syndrome-results from a 6-month, double-blind, randomized controlled trial
Curtis PJ, van der Velpen V, Berends L, Jennings A, Feelisch M, Umpleby AM, Evans M, Fernandez BO, Meiss MS, Minnion M, Potter J, Minihane AM, Kay CD, Rimm EB, Cassidy A
The American journal of clinical nutrition · 185 citas
Etiquetas de revisión
Alimentación controladaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- Comida provista por los investigadores
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- U.S. Department of Agriculture
- Universidad u hospital
- University of Cambridge
- Universidad u hospital
- University of East Anglia
- Universidad u hospital
- University of Surrey
- Gobierno
- Directorate for Biological Sciences
- Gobierno
- Biotechnology and Biological Sciences Research Council
Según 6 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2018-12-12 · Am J Clin Nutr · vol. 109 · número 6 · págs. 1535–1545
- Editorial
- Elsevier BV
- Citado
- 251 citas · más que el 99% de estudios similares · 8.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 60 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY
- Áreas de investigación
- Phytochemicals and Antioxidant Activities · Pharmacology and Obesity Treatment · Sirtuins and Resveratrol in Medicine
- Palabras clave
- Insulin resistance, Medicine, Internal medicine, Metabolic syndrome, Type 2 diabetes, Endocrinology, Insulin, Body mass index, Lipoprotein, Lipoprotein particle, Homeostatic model assessment, Diabetes mellitus, Cholesterol, Very low-density lipoprotein
- MeSH
- heart, humans, fruit, insulin resistance, apolipoproteins, prospective studies, double-blind method, blood pressure, aged, middle aged, female, male, cholesterol, ldl, cholesterol, hdl, pulse wave analysis, biomarkers, blueberry plants, metabolic syndrome
15 autores
- Peter J. Curtis🇬🇧University of East Anglia
- Vera van der Velpen🇬🇧University of East Anglia
- Lindsey M. Berends🇬🇧University of East Anglia
- Amy Jennings🇬🇧University of East Anglia
- Martin Feelisch🇬🇧University Hospital Southampton NHS Foundation Trust; University of Southampton
- Anne Margot Umpleby🇬🇧University of Surrey
- Mark L. Evans🇬🇧University of Cambridge; Wellcome/MRC Institute of Metabolic Science; Wellcome Trust
- Bernadette O. Fernandez🇬🇧University Hospital Southampton NHS Foundation Trust; University of Southampton
- Mia S Meiss🇬🇧University Hospital Southampton NHS Foundation Trust; University of Southampton
- Magdalena Minnion🇬🇧University Hospital Southampton NHS Foundation Trust; University of Southampton
- John F. Potter🇬🇧University of East Anglia
- Anne Marie Minihane🇬🇧University of East Anglia
- Colin D. Kay🇬🇧University of East Anglia
- Eric B. Rimm🇺🇸Brigham and Women's Hospital; Harvard University
- Aedín Cassidy🇬🇧 · autor de correspondenciaUniversity of East Anglia
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Anthocyanin-rich blueberry intake is associated with reduced type 2 diabetes and cardiovascular disease (CVD) risk in prospective studies, although long-term randomized controlled trials (RCTs) have not been conducted in at-risk populations.
Objective
In the longest-duration RCT to date, we examined the effect of 6-mo blueberry intake on insulin resistance and cardiometabolic function in metabolic syndrome.
Methods
A double-blind, parallel RCT (n = 115; age 63 ± 7 y; 68% male; body mass index 31.2 ± 3.0 kg/m2) was conducted, which fed 2 dietarily achievable blueberry intakes [equivalent to 1/2 and 1 cup/d (75/150 g)] compared with matched placebo. Insulin resistance was assessed via the homeostasis model assessment of insulin resistance (primary endpoint) and confirmed by [6-6-2H2]-glucose-labeled, 2-step hyperinsulinemic clamp (n = 20). Clinically relevant cardiometabolic endpoints [including flow-mediated dilatation, augmentation index, lipoprotein status (by nuclear magnetic resonance spectroscopy), and nitric oxide (NO)-related metabolite assay] and anthocyanin metabolism were assessed.
Results
A daily intake of 1 cup of blueberries improved endothelial function (flow-mediated dilatation: +1.45%; 95% CI: 0.83%, 2.1%; P = 0.003), systemic arterial stiffness (augmentation index: -2.24%; 95% CI: -3.97%, -0.61%; P = 0.04) and attenuated cyclic guanosine monophosphate concentrations. In statin nonusers (n = 71), elevated high-density lipoprotein cholesterol (+0.08 mmol/L; P = 0.03), high-density lipoprotein particle density (+0.48n, ×10-6; P = 0.002) and apolipoprotein A-I (+0.05 g/L; P = 0.01) concentrations were observed following the 1-cup/d intervention. Treatment compliance was 94.1% (wrapper returns) and total concentrations of anthocyanin-derived phenolic acid metabolites significantly increased, dose-dependently, in serum and 24-h urine (P < 0.01 and P < 0.001, respectively). Insulin resistance, pulse wave velocity, blood pressure, NO, and overall plasma thiol status were unaffected. Likewise, a half cup per day had no effect on any biomarkers.
Conclusions
Despite insulin resistance remaining unchanged we show, to our knowledge, the first sustained improvements in vascular function, lipid status, and underlying NO bioactivity following 1 cup blueberries/d. With effect sizes predictive of 12-15% reductions in CVD risk, blueberries should be included in dietary strategies to reduce individual and population CVD risk. This study was registered at clinicaltrials.gov as NCT02035592.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.